PCSA
NASDAQProcessa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc. (PCSA) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 10 wire items for PCSA, including 8 SEC filings, 1 leadership change and 1 press release or news item. The most recent was published Nov 4, 2026.
PCSA rankings
Financial highlights
Full financials- Net income, TTM
- -$13.44M
- Cash
- $196.3K
For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks52+50%
2026-05-102026-11-01
Mix1290d
- SEC Filings8(67%)
- Other2(17%)
- Insider1(8%)
- Leadership1(8%)
Latest news
25 items- SECProcessa Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits8-K - Processa Pharmaceuticals, Inc. (0001533743) (Filer)
- PRProcessa Pharmaceuticals Announces Key Leadership AppointmentsVERO BEACH, FL, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) ("Processa" or the "Company"), a clinical-stage pharmaceutical company advancing differentiated therapeutic programs for immunological and inflammatory diseases, today announced key leadership appointments to support the Company’s next phase of growth: Gregory J. Flesher, Chief Operating OfficerCraig Coburn, Ph.D., Executive Vice President, Head of ResearchAshley Hall, J.D., Executive Vice President, DevelopmentMichael P. Cruse, Executive Vice President, Business Operations "As we advance our Bruton’s tyrosine kinase inhibitor VT-7208 across multiple immune-mediated diseases and continue to exp
- SECSEC Form 8-K filed by Processa Pharmaceuticals Inc.8-K - Processa Pharmaceuticals, Inc. (0001533743) (Filer)
- PRProcessa Pharmaceuticals Announces Corporate and Pipeline Progress Following Acquisition of Vidya TherapeuticsU.S. FDA clears IND for Phase 2 study of VT-7208 in chronic spontaneous urticaria; additional Phase 2 studies planned in food allergy and relapsing multiple sclerosisCompany expands pipeline through research collaboration of a novel, oral macrocyclic peptide-based neonatal Fc receptor antagonist program from Generian Pharmaceuticals Sheila Gujrathi, M.D., appointed Executive Chair of Processa’s Board of DirectorsCash runway expected to fund operations into the second half of 2029 VERO BEACH, FL, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) ("Processa" or the "Company"), a clinical-stage pharmaceutical company developing VT-7208, a Bruton's tyrosine kinas
- SECSEC Form EFFECT filed by Processa Pharmaceuticals Inc.EFFECT - Processa Pharmaceuticals, Inc. (0001533743) (Filer)
- SECSEC Form DEF 14A filed by Processa Pharmaceuticals Inc.DEF 14A - Processa Pharmaceuticals, Inc. (0001533743) (Filer)
- SECSEC Form PRE 14A filed by Processa Pharmaceuticals Inc.PRE 14A - Processa Pharmaceuticals, Inc. (0001533743) (Filer)
- SECSEC Form PRE 14A filed by Processa Pharmaceuticals Inc.PRE 14A - Processa Pharmaceuticals, Inc. (0001533743) (Filer)
- SECSEC Form S-3 filed by Processa Pharmaceuticals Inc.S-3 - Processa Pharmaceuticals, Inc. (0001533743) (Filer)
- SECAmendment: Processa Pharmaceuticals Inc. filed SEC Form 8-K: Financial Statements and Exhibits8-K/A - Processa Pharmaceuticals, Inc. (0001533743) (Filer)
- PRProcessa Pharmaceuticals to Participate in Upcoming Investor ConferencesVERO BEACH, FL, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), a clinical-stage pharmaceutical company developing VT-7208, a Bruton's tyrosine kinase (BTK) inhibitor therapy for immune-mediated diseases, today announced its participation in two upcoming investor conferences. Sheila Gujrathi, M.D., a member of the Processa board of directors and founder and former executive chair of Vidya Therapeutics, will give a company presentation at the following: Thursday, September 10, at 10:15 a.m. ET at the Wells Fargo 21st Annual Healthcare Conference. Register for the webcast here. Friday, September 11, at 7 a.m. ET at the H.C. Wainwright 28th Annual Global In
- INSIDERChief Executive Officer Ng George K converted options into 1,600 shares, increasing direct ownership by 10% to 17,092 units (SEC Form 4)4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- SECSEC Form 8-K filed by Processa Pharmaceuticals Inc.8-K - Processa Pharmaceuticals, Inc. (0001533743) (Filer)
- INSIDERSEC Form 4 filed by Director Gujrathi Sheila4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- INSIDERSEC Form 3 filed by new insider Gujrathi Sheila3 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- SECProcessa Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Processa Pharmaceuticals, Inc. (0001533743) (Filer)
- PRPROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREASAcquisition brings into Processa’s pipeline Vidya’s lead asset, VT-7208, a next-generation, CNS-penetrant, once-daily, oral potentially best-in-class Bruton’s tyrosine kinase inhibitor (BTKi) designed to overcome the efficacy and safety limitations of early-generation BTKi programsConcurrent oversubscribed private placement financing of approximately $200 million committed by a syndicate of leading healthcare institutional investors and mutual fundsPrivate placement proceeds are expected to fund operations into the second half of 2029 and through key clinical milestones, including top-line data from Phase 2 proof-of-concept studies for food allergy, chronic spontaneous urticaria (CSU), and r
- INSIDERSEC Form 4 filed by Director Yorke Justin W4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Skibsted Russell4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- INSIDERSEC Form 4 filed by Director Pannu Geraldine4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Ng George K4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- INSIDERSEC Form 4 filed by Director Neal James R4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- INSIDERSEC Form 4 filed by Chief Business - Strategy Off Lin Patrick4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- INSIDERSEC Form 4 filed by Chief Administrative Officer Guy Wendy4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- INSIDERSEC Form 4 filed by Director Baluch Khoso4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
PCSA FAQ
9 questionsWhat does Processa Pharmaceuticals Inc. do?
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase II clinical trials for the treatment of necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase II clinical trials for the treatment of gastroparesis; and PCS6422, an oral, potent, selective, and irreversible...What is the latest news on PCSA?
In the last 30 days Quantisnow tracked 10 wire items for PCSA: 8 SEC filings, 1 leadership change and 1 press release or news item. The most recent was published on November 4, 2026.Is PCSA profitable?
No. Processa Pharmaceuticals Inc. reported a net loss of $13.44M for the twelve months ended Jun 30, 2026.How much cash and debt does PCSA have?
Processa Pharmaceuticals Inc. reported $196.3K in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does PCSA stock trade?
Processa Pharmaceuticals Inc. (PCSA) is listed on NASDAQ.What sector and industry is PCSA in?
Processa Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about PCSA?
Processa Pharmaceuticals Inc. has had 3 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $8.00 price target on 2024-04-25. Recent price targets range from $8.00 to $20.00.What companies are similar to PCSA?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare PCSA side-by-side with any of them on Quantisnow.How can I track PCSA on Quantisnow?
Quantisnow aggregates Processa Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PCSA to receive live email and push alerts on every new disclosure.